Originally published by Destiny Pharma, 22 July 2024. This clinical data was generated prior to AMR Bio’s acquisition of the XF platform and represents part of the Phase 2 clinical evidence base AMR Bio is advancing towards Phase 3.
New clinical data from Destiny Pharma’s Phase 2b clinical trial on XF-73 in cardiac surgery patients was presented at the ID Week conference, the joint annual meeting of the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.
Significantly fewer patients in the XF-73 treatment arm received post-operative anti-staphylococcal antibiotics: 46.5% (20 of a total population of 43), compared to 70% (28 of a total population of 40) in the placebo group, p=0.045. This builds on the previously reported primary endpoint of greater than 99% reduction in nasal S. aureus compared to placebo one hour before open heart surgery (p < 0.0001).
The observed reduction of the use of post-operative antibiotics in the XF-73 arm is consistent with the principles of good antimicrobial stewardship which are crucial for managing and preventing infections more effectively and for maintaining the efficacy of antibiotics, reducing healthcare complications, and improving patient safety.
Additional advantages of XF-73 Nasal gel include the short, 24-hour, pre-surgical dosing regimen, rapidity of S. aureus nasal decolonisation, remote likelihood of resistance emergence, and the duration of effect. Phase 3 studies are being planned to evaluate and gain regulatory approval for XF-73.
Read the original announcement in full here: https://destinypharma.com/2024/07/22/treatment-of-xf-73-nasal-reduces-antibiotic-use/